Please login to the form below

Not currently logged in
Email:
Password:

Envigo appoints Dr Adrian Hardy as president and CEO

He succeeds Brian Cass in the role

UK research services company Envigo has appointed Dr Adrian Hardy as its new president and chief executive officer, which will take effect from 1 July.

He will succeed Brian Cass in the role who becomes executive chairman, while the previous chairman Andrew Baker becomes chairman emeritus.

Dr Hardy first joined Envigo in 2002 in a business development role, before taking on a series of increasingly senior posts, most recently having served as chief operating officer at the firm.

Prior to joining Envigo, Dr Hardy was a product development manager for Novartis, and served as a director at law firm iPulse.

Dr Hardy said: “I'm delighted and extremely proud to be taking on this role at such an exciting time for Envigo and the research community.

“I've worked closely with Andrew and Brian during my time with the company and would like to thank them for their contributions to making Envigo the world class company it is today.

“Their vision and leadership has positioned our company as a market leader, and I look forward to continuing to work with them in their new roles as we strive to build on the growth and success of Envigo.”

30th June 2016

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
claire@dovetailstrategies.com

About Dovetail We’re award-winning specialists in healthcare collaboration that makes patients’ lives better. Combining expertise with a passion for collaboration,...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics